UK approval vs NHS access
The Wegovy pill contains semaglutide, the same drug as the Wegovy injection, taken as a tablet once a day rather than an injection once a week.
Like the injection, it mimics a hormone called GLP-1, which reduces appetite and quiets food noise (the constant intrusive thoughts about food).
In the OASIS 4 trial, people taking the pill lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on placebo.2
The MHRA’s approval means the pill has met the UK’s standards for safety, quality, and effectiveness, and can be prescribed here once Novo Nordisk launches it.
The licence covers adults with a BMI of 30 or higher, or a BMI of 27 to 29.9 with at least one weight-related condition.1
Approval doesn’t make a medication available on the NHS, though. Those are two separate decisions, made by two different organisations.
Our guide to the Wegovy pill covers how it works, its side effects, and the full daily routine.
The three steps between approval and NHS prescriptions
Three things have to happen before you can get a new weight-loss medication through the NHS:
- MHRA approval: the regulator confirms the medication is safe and effective enough to be prescribed in the UK. This step is now complete for the Wegovy pill.
- A NICE recommendation: NICE assesses whether the medication is good value for the NHS, comparing its cost against the health benefit it produces. This is the step that decides NHS funding.
- Local rollout: NHS services in each area need the capacity to assess patients and prescribe, which is why access to weight-loss medications often varies by postcode.
For the Wegovy pill, the NICE step is where things currently stand.
NICE first planned to assess oral semaglutide for weight management in 2022, but discontinued that appraisal in 2025 after Novo Nordisk chose not to submit evidence at the time.3
Now that the pill is approved, a NICE assessment is the next step before the NHS can fund it.
When NICE recommends a medication, the NHS is normally required to start funding it within 3 months.
For weight-loss medications, longer phased rollouts have been agreed instead.
Our guide to Mounjaro on the NHS covers the clearest example: GP prescribing started in June 2025, with the highest-need patients first, and the full rollout is planned over 12 years.
When the Wegovy pill could be available on the NHS
There’s no confirmed date yet. The closest guide is how injectable Wegovy became available on the NHS.
Injectable Wegovy was approved by the MHRA in September 2021.
NICE recommended it about 18 months later, in March 2023, and it reached NHS prescriptions in September 2023, roughly 2 years after approval.4
If the pill follows a similar path, NHS access would most likely begin in 2028.
It could be sooner, because NICE has already recommended the same drug for the same purpose in its injectable form.
It could also be later if pricing negotiations take time, or if a phased rollout is agreed, as happened with Mounjaro.
Even after a positive decision, access tends to build up gradually because most NHS prescribing of weight-loss medications goes through specialist weight management services with limited capacity and long waiting lists.
Who’s likely to qualify on the NHS
NHS eligibility criteria are stricter than the licence, so being in the licensed group doesn’t guarantee access to the NHS.
NICE hasn’t published criteria for the pill yet. The most likely starting point is the criteria it already uses for injectable Wegovy:4
- A BMI of 35 or higher, with at least one weight-related condition, such as type 2 diabetes, high blood pressure, or sleep apnoea (interrupted breathing during sleep)
- In some cases, a BMI of 30 to 34.9, if you meet the criteria for referral to a specialist weight management service
- Lower BMI thresholds (usually reduced by 2.5) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds
- Treatment through a specialist weight management service, rather than directly from your GP
- NHS funding for a maximum of 2 years
Our free eligibility checker covers the criteria for Wegovy and Mounjaro, the two weight-loss injections licensed in the UK, and tells you whether you’re likely to qualify privately, through the NHS, or whether you fall outside the criteria.
The 2-year NHS limit is one reason we recommend using time on any weight-loss medication to build the eating, activity, and sleep habits that help to support sustainable weight loss and prevent weight regain.
The Wegovy pill vs the Wegovy injection on the NHS
Our guide to getting Wegovy on the NHS covers the injection’s criteria and application route step by step.
|
Wegovy pill |
Wegovy injection (2.4 mg) |
| NHS availability |
Not yet, the NICE assessment is the next step |
Available through specialist weight management services, if you meet the criteria |
| Private availability |
Expected within weeks, according to Novo Nordisk |
Available now |
| How you take it |
A tablet once a day, on an empty stomach |
An injection once a week |
| Average weight loss in trials |
13.6% over 64 weeks (OASIS 4)2 |
14.9% over 68 weeks (STEP 1)5 |
| Time to the full dose |
About 12 weeks |
About 16 weeks |
The average weight-loss results are broadly comparable, with a difference of about 1 percentage point between the pill and the 2.4 mg injection in their respective main trials.
There’s also a higher 7.2 mg injectable dose, approved in the UK in January 2026, which produced an average weight loss of 20.7% in the STEP UP trial and is currently available privately.6
Our Wegovy pill vs injection comparison covers effectiveness, side effects, cost, and the daily routine in more detail.
What you can do now
Waiting for the pill isn’t your only option, because the same drug is already available in other forms.
- Check whether you’d qualify today: injectable Wegovy and Mounjaro are both available on the NHS and privately, each with different criteria. Our GLP-1 BMI calculator above provides an answer in 1 minute.
- Talk to your GP about the NHS route: GPs can refer you to a specialist weight management service, where injectable Wegovy can be prescribed if it’s suitable. Our guide on how to talk to your GP about your weight covers how to prepare for that conversation.
- Consider a private prescription: private providers can now prescribe injectable Wegovy, and Novo Nordisk expects the pill to be available privately within weeks of approval. Our guide to private Wegovy prescriptions in the UK covers costs and the process.
Second Nature has worked with the NHS since 2017, combining weight-loss medication with structured habit support from registered dietitians and nutritionists. Take our 3-minute eligibility quiz, and a clinician will review your answers.
Frequently asked questions
Is the Wegovy pill available on the NHS now?
No. The pill was approved in the UK on 11th June 2026, but its availability on the NHS requires a separate NICE recommendation, which hasn’t been issued yet.1
When will the Wegovy pill be available on the NHS?
Most likely in 2028, if NICE recommends it.
That estimate is based on injectable Wegovy, which took about 18 months from UK approval to a NICE recommendation and about 2 years to reach NHS prescription status.
It could come sooner, because NICE has already recommended the same drug for injection.
Can my GP prescribe the Wegovy pill?
No, not at the moment, because the pill isn’t available on the NHS yet.
Even once it is, NHS prescribing of Wegovy currently runs through specialist weight management services rather than GP surgeries, so expect a referral rather than a direct prescription.
Who’s likely to qualify for the Wegovy pill on the NHS?
If NICE follows its approach to injectable Wegovy, the likely criteria are a BMI of 35 or higher with at least one weight-related condition, or a BMI of 30 to 34.9 if you meet the criteria for a specialist referral, with treatment limited to 2 years within a specialist service.4
Is the Wegovy pill as effective as the injection?
The results are very close. The pill produced an average weight loss of 13.6% over 64 weeks in OASIS 4, and the 2.4 mg injection produced 14.9% over 68 weeks in STEP 1.2,5
Side effects are also similar, mostly digestive. In OASIS 4, 74% of people on the pill had gastrointestinal side effects, compared with 42% on placebo.2
Can I get the Wegovy pill privately now that it’s approved?
Not quite yet. Approval means private prescribing can start once Novo Nordisk launches the pill in the UK, which the company expects to happen within weeks of approval.
Private providers are expected to offer it before the NHS does, as happened with injectable Wegovy and Mounjaro.
Is the Wegovy pill the same as Rybelsus?
No. Both are semaglutide tablets, but Rybelsus comes in doses up to 14 mg and is licensed for type 2 diabetes, while the Wegovy pill is a 25 mg dose licensed for weight management.
Our guide to oral weight-loss medications in the UK compares the Wegovy pill, Foundayo, and Rybelsus.
Will I be able to switch from Wegovy injections to the pill on the NHS?
Nobody will be switched automatically. If the pill is recommended for NHS use, switching from the injection to the pill is a decision to make with your prescriber, based on your dose, your progress, and how you manage the daily routine.
How is the Wegovy pill taken?
One tablet, first thing in the morning, on an empty stomach. You swallow it whole with up to half a glass of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications.
Doses start at 1.5 mg and increase roughly every month, reaching 4 mg and 9 mg before the full 25 mg dose.1
Take home message
You can’t get the Wegovy pill on the NHS yet. It’s now approved in the UK, and the NHS funding decision sits with NICE.
If NICE recommends it, NHS access would most likely begin in 2028 through specialist weight management services, with strict eligibility criteria, as with the injection.
Injectable Wegovy is already available on the NHS if you meet the criteria, and privately if you don’t or if the waiting lists in your area are long.
The pill is expected to reach private providers first, so it may become an option months before the NHS route opens.
Whichever route you take, the research suggests you’re more likely to avoid weight regain when a medication is combined with structured habit support than when it’s prescribed on its own.
At Second Nature, we combine weight-loss medication with structured habit support from registered dietitians and nutritionists, and we’ve worked with the NHS for over 6 years.
In a published study of our semaglutide-supported programme, members lost an average of 19.1% of their body weight at 12 months, and 77.7% lost at least 10%.7
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
